Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanshinone Capsules for COVID-19
NCT07123701Phase 3Completed
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Negative conversion time of nucleic acid in throat swab. Started Mar 2024; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07123701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123701.